Welcome TVM Clinical Evidence How to Buy / Clinical Training US Reimbursement Investor Relations Contact Us

Back

Grant of Options

01 July 2008 – Deltex Medical Group plc ('the Company'), the UK's leading haemodynamic monitoring company, announces that the Board yesterday approved the issue of share options to its executive members.

The Board has approved the issue of contractual share options to Andy Hill, Chief Executive, and Ewan Phillips, Finance Director, under the Company's 2001 Executive Share Option Scheme as follows:

NameNo. of OptionsExcercise Price
(£)
Excercise Period
From
Excercise Period
To
Andy Hill500,0000.18530 June 201129 June 2018
Ewan Phillips500,0000.18530 June 201129 June 2018

In addition, the Company's 2003 Enterprise Management Incentive Scheme ('EMI Scheme') allows directors and employees who have earned performance related bonus payments under the terms of their employment to sacrifice their entitlement to cash payment in return for share options at the nominal value of 1p per share. The EMI Scheme is designed to allow managers to align their interests with those of shareholders by building a meaningful equity interest in the Company while preserving the Company's cash resources for investment in its operations. In the event that the share price on exercise and sale of an EMI Scheme option share is higher than at the date of bonus sacrifice, the EMI Scheme is potentially tax efficient for the scheme member. However, if the share price on exercise and sale of an EMI Scheme option share is lower than at the date of award, the individual will realise an amount after tax that is lower than the amount of bonus originally sacrificed.

Andy Hill has elected to sacrifice part (£20,000) of the performance bonus and Ewan Phillips has elected to sacrifice the whole (£60,000) of the performance bonus awarded by the Company's Remuneration Committee in respect of the year ended 31 December 2007, resulting in awards of options under the EMI Scheme as follows:

NameNo. of OptionsExcercise Price
(£)
Excercise Period
From
Excercise Period
To
Andy Hill114,2860.01See note (a)29 June 2018
Ewan Phillips342,8570.01See note (a)29 June 2018

Note (a). Date of announcement of preliminary results for the year ended 31 December 2008.

In addition to the options outlined above, Mr Hill has an interest in the following:

NameNo. of OptionsExcercise Price
(£)
Excercise Period
From
Excercise Period
To
Executive Share 200,0000.2527 November 200526 November 2012
Option Scheme200,0000.1528 October 200627 October 2013
 400,0000.2412 October 200711 October 2014
 400,0000.207528 March 200927 March 2016
 400,0000.29529 June 201028 June 2017
EMI Scheme333,3330.124 March 200427 October 2013
 156,7390.115 March 200511 October 2014
 154,0850.115 March 200719 May 2016
 314,6150.127 March 200828 June 2017

In addition to the options outlined above, Mr Phillips has an interest in the following:

NameNo. of OptionsExcercise Price
(£)
Excercise Period
From
Excercise Period
To
Executive Share 100,0000.257 November 20046 November 2011
Option Scheme60,0000.2527 November 200526 November 2012
 120,0000.1528 October 200627 October 2013
 400,0000.2412 October 200711 October 2014
 400,0000.207528 March 200927 March 2016
 400,0000.29529 June 201028 June 2017
EMI Scheme583,3330.124 March 200427 October 2013
 156,7390.115 March 200511 October 2014
 259,2250.115 March 200719 May 2016
 235,9620.127 March 200828 June 2017

Mr Hill also has a beneficial interest in 179,334 ordinary shares in the Company representing 0.18 per cent of the issued ordinary share capital of the Company.

Mr Phillips also has a beneficial interest in 977,156 ordinary shares in the Company representing 0.97 per cent of the issued ordinary share capital of the Company.

All shares and options relate to ordinary 1p shares.

For further information, please contact:

Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman: njk@deltexmedical.com
Andy Hill, Chief Executive: ahill@deltexmedical.com
Ewan Phillips, Finance Director: eap@deltexmedical.com